Randomized trial evaluates oral NAM and PL for reducing UVA-induced erythema in healthy volunteers, suggesting potential benefits for skin health.
Background Nicotinamide (NAM) and Polypodium leucotomos extract (PL) have demonstrated photoprotective effects, but their role in preventing UVA-induced DNA damage in humans remains unclear. Objective To evaluate the effects of oral NAM and PL on UVA-induced erythema and thymidine dimer (TT-dimer) formation. Methods In this intraindividual trial, 50 healthy volunteers (phototypes I–III) were randomized (1:1) to receive either NAM (2000 mg daily) or PL (Heliocare Advanced: 480 mg daily) for 30 days. UVA-induced erythema, assessed by minimal erythema dose (MED), and TT-dimers, quantified in urine and skin biopsies, were measured before and after treatment with NAM or PL. Results Both NAM and PL increased MED by 26%. With a median MED of 27.7 J/cm² (13.4–51.1 J/cm²) pre-NAM and 34.8 J/cm² (13.4–62.5 J/cm²) post-NAM ( p = 0.0008). And A median MED of 27.7 J/cm² (13.4–51.1 J/cm²) pre-PL and 34.8 J/cm² (16.4–62.5 J/cm²) post-PL ( p = 0.0002). Neither treatment reduced UVA-induced TT-dimers in skin (NAM: p = 0.15; PL: p = 0.15) or urine (NAM: p = 0.89; PL: p = 0.30). Limitations NAM and PL were not administered during the urine collection-period, which limited the assessment of the treatment’s effect after radiation. Conclusion UVA-induced erythema was significantly reduced by PL and NAM, but neither had measurable effects on TT-dimer induction. Further research should investigate the relation between these findings and the chemopreventive effect of NAM and PL on skin cancer.
No takes yet. Share an insight, caveat, or question.
Faisal et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: